ArticleNEJM evidence2024
Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022-2023.
Article in NEJM evidence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global epidemiology, viral evolution, and public health responses: a systematic review on Mpox (1958-2024).Journal of global health · 2025Pooled it
- Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial.The Lancet. Microbe · 2026Trial
- Treatment of mpox with tecovirimat under expanded access use in the Central African Republic.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Article
- Monovalent Nondegrading Molecular Glues: An Updated Overview of Emerging Mechanisms and Therapeutic Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- Recent advances in Mpox across innate immunity, evasion, and clinical outcomes.Communications biology · 2026Review
- Long-Term Mpox Sequelae 11 to 18 Months After Acute Illness : A Cohort Study in Two U.S. Cities.Annals of internal medicine · 2026Article
- Insights into Monkeypox Virus: Host Immunity, Viral Immune Evasion, Recent Advances in Vaccines, Therapeutic Development, and Future Perspectives.Microorganisms · 2026Review
- Monkeypox Virus Countermeasures: Vaccines, Antibodies, Drugs and Traditional Chinese Medicine.Drug design, development and therapy · 2026Review
- Review
- Intervention timing and disease stage shape tecovirimat and cidofovir efficacy in male SCID mice.Nature communications · 2025Article
- Mpox in people living with HIV in Brazil: spatial distribution, clinical features, and outcomes from a nationwide surveillance study.Lancet regional health. Americas · 2025Article
- Mpox in People Living with HIV: Clinical Challenges, Preventive Strategies and Public Health Implications.Viruses · 2025Review
- Mpox: disease manifestations and therapeutic development.Journal of virology · 2025Review
- Drug screen reveals new potent host-targeted antivirals against Mpox virus.Research square · 2025Article
- 3D-EDiffMG: 3D equivariant diffusion-driven molecular generation to accelerate drug discovery.Journal of pharmaceutical analysis · 2025Article
- Drug screen reveals new potent host-targeted antivirals against Mpox virus.bioRxiv : the preprint server for biology · 2025Article
- Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics.Advanced healthcare materials · 2025Review
- Monkeypox Virus: WHO's Second Public Health Emergency of International Concern Within 2 Years.Microbial biotechnology · 2025Review
- Clinical Predictors and Determinants of Mpox Complications in Hospitalized Patients: A Prospective Cohort Study from Burundi.Viruses · 2025Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
backgroundDuring the ongoing outbreak of clade II
methodsWe evaluated data from patients prescribed tecovirimat from May 29, 2022, through July 10, 2023. Baseline patient characteristics, clinical courses, and outcomes were evaluated via intake forms, outcome forms, and patient diaries. Data were summarized in aggregate by human immunodeficiency virus (HIV) status and by comorbidities of special interest. Reported SAEs were also compiled.
resultsTecovirimat was prescribed for over 7100 patients in the United States, most often for lesions in sensitive anatomical areas, such as certain anogenital lesions (83.5%; 5135 out of 6148 patients), and pain (52.5%; 3227 out of 6148 patients). The demographic and clinical characteristics mirrored those of patients worldwide. Among the 7181 patients with returned intake forms, 1626 also had returned outcome forms (22.6%). Many patients with severe immunocompromise (e.g., HIV with CD4 counts <200 cells/μl) received multiple courses of tecovirimat (43.1%; 22 out of 51 patients), including intravenously, and often experienced poor outcomes (35.3%; 18 out of 51 patients). Overall, 223 SAEs and 40 deaths were reported. Most SAEs were among patients who were severely immunocompromised, one of whom experienced hallucinations after tecovirimat was administered at twice the standard dose.
conclusionsTecovirimat was used extensively. The returned EA-IND data suggest that life-threatening or protracted infections occurred in persons who were severely immunocompromised. SAEs were not commonly reported. The EA-IND data are not definitive; controlled clinical trial data are essential to elucidating if and how tecovirimat should be used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.